Carolyn J Presley1, Ling Han2, John R O'Leary2, Weiwei Zhu2, Emily Corneau3, Herta Chao2,4, Tracy Shamas4, Michal Rose2,4, Karl Lorenz5, Cari R Levy6, Vincent Mor3,7, Cary P Gross8. 1. Department of Internal Medicine, Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. 2. Yale University School of Medicine, New Haven, Connecticut, USA. 3. Providence Veterans Health Administration Medical Center, Center of Innovation, Providence, Rhode Island, USA. 4. Connecticut Veterans Health Administration Medical Center, West Haven, Connecticut, USA. 5. Department of Medicine, Primary Care and Population Health, Stanford University, Palo Alto, California, USA. 6. Eastern Colorado VA Healthcare System, Aurora, Colorado, USA. 7. Department of Health Services, Policy and Practice, Brown University School of Public Health, Providence, Rhode Island, USA. 8. National Clinician Scholars Program, Yale School of Medicine, New Haven, Connecticut, USA.
Abstract
Background: Aggressive care at the end of life (EOL) is a persistent issue for patients with stage IV nonsmall cell lung cancer (NSCLC). We evaluated the use of concurrent care (CC) with hospice care and cancer-directed treatment simultaneously within the Veteran's Health Administration (VHA) and aggressive care at the EOL. Objective: To determine whether VHA facility-level CC is associated with changes in aggressive care at the EOL. Design/Setting: Veterans with stage IV NSCLC who died between 2006 and 2012 and received lung cancer care within the VHA. Measurements: The primary outcome was aggressive care at EOL (i.e., hospital admissions, chemotherapy, and intensive care unit) within the last month of life. To compare aggressive care across VHA facilities, we used a random intercept multilevel logistic regression model to examine the association between facility-level CC within each study year (<10%, 10% to 19%, and ≥20%) and aggressive care at the EOL among the decedents as a binary outcome. Results: In total, 18,371 veterans with NSCLC at 154 VHA facilities were identified. Facilities delivering CC for ≥20% of veterans (high CC) increased from 20.0% in 2006 to 43.2% in 2012 (p < 0.001). Overall, hospice care significantly increased and aggressive care at EOL decreased over the study period. However, facility-level CC adoption was not associated with any difference in aggressive care at EOL (adjusted odds ratio high CC vs. low CC: 0.91 [95% CI, 0.79 to 1.05], p = 0.21). Conclusions: Although the VHA adoption of CC increased hospice use among patients with NSCLC, additional measures may be needed to decrease aggressive care at the EOL.
Background: Aggressive care at the end of life (EOL) is a persistent issue for patients with stage IV nonsmall cell lung cancer (NSCLC). We evaluated the use of concurrent care (CC) with hospice care and cancer-directed treatment simultaneously within the Veteran's Health Administration (VHA) and aggressive care at the EOL. Objective: To determine whether VHA facility-level CC is associated with changes in aggressive care at the EOL. Design/Setting: Veterans with stage IV NSCLC who died between 2006 and 2012 and received lung cancer care within the VHA. Measurements: The primary outcome was aggressive care at EOL (i.e., hospital admissions, chemotherapy, and intensive care unit) within the last month of life. To compare aggressive care across VHA facilities, we used a random intercept multilevel logistic regression model to examine the association between facility-level CC within each study year (<10%, 10% to 19%, and ≥20%) and aggressive care at the EOL among the decedents as a binary outcome. Results: In total, 18,371 veterans with NSCLC at 154 VHA facilities were identified. Facilities delivering CC for ≥20% of veterans (high CC) increased from 20.0% in 2006 to 43.2% in 2012 (p < 0.001). Overall, hospice care significantly increased and aggressive care at EOL decreased over the study period. However, facility-level CC adoption was not associated with any difference in aggressive care at EOL (adjusted odds ratio high CC vs. low CC: 0.91 [95% CI, 0.79 to 1.05], p = 0.21). Conclusions: Although the VHA adoption of CC increased hospice use among patients with NSCLC, additional measures may be needed to decrease aggressive care at the EOL.
Entities:
Keywords:
concurrent care; end-of-life; hospice; lung cancer; quality of life
Authors: Akiko M Saito; Mary Beth Landrum; Bridget A Neville; John Z Ayanian; Jane C Weeks; Craig C Earle Journal: J Palliat Med Date: 2011-07-18 Impact factor: 2.947
Authors: Jennifer S Temel; Joseph A Greer; Alona Muzikansky; Emily R Gallagher; Sonal Admane; Vicki A Jackson; Constance M Dahlin; Craig D Blinderman; Juliet Jacobsen; William F Pirl; J Andrew Billings; Thomas J Lynch Journal: N Engl J Med Date: 2010-08-19 Impact factor: 91.245
Authors: Risha Gidwani; Nina Joyce; Bruce Kinosian; Katherine Faricy-Anderson; Cari Levy; Susan C Miller; Mary Ersek; Todd Wagner; Vincent Mor Journal: J Palliat Med Date: 2016-05-26 Impact factor: 2.947
Authors: Carolyn J Presley; Kiranveer Kaur; Ling Han; Pamela R Soulos; Weiwei Zhu; Emily Corneau; John R O'Leary; Herta Chao; Tracy Shamas; Michal G Rose; Karl A Lorenz; Cari R Levy; Vincent Mor; Cary P Gross Journal: J Palliat Med Date: 2022-03-30 Impact factor: 2.947
Authors: Ann M O'Hare; Catherine R Butler; Janelle S Taylor; Susan P Y Wong; Elizabeth K Vig; Ryan S Laundry; Melissa W Wachterman; Paul L Hebert; Chuan-Fen Liu; Nilka Rios-Burrows; Claire A Richards Journal: J Am Soc Nephrol Date: 2020-08-06 Impact factor: 10.121
Authors: F Amos Bailey; Beverly R Williams; Patricia S Goode; Richard E Kennedy; David T Redden; Elizabeth Kvale; Marie Bakitas; J Nicholas Dionne-Odom; Kathryn L Burgio Journal: J Gen Intern Med Date: 2021-02-05 Impact factor: 6.473